NCT07789119尚未招募不适用
Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 50,000
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.
详细描述
The primary objectives of this protocol are to prospectively collect, process, store, and clinically annotate biospecimens and associated data from participants with urothelial carcinoma and related malignancies of the urinary tract in order to support translational research addressing clinically important scientific questions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligibility Criteria
- •Participants must meet all of the following criteria for enrollment:
- •Age 18 years or older at the time of consent.
- •Known or suspected urothelial carcinoma or other related malignancy of the urinary tract for which biospecimen and associated clinical data collection is relevant to the objectives of this protocol. This may include patients undergoing diagnostic evaluation for a lesion, mass, abnormal cytology, or other clinical finding concerning for malignancy.
- •Undergoing evaluation, treatment, surveillance, follow-up care, or clinically indicated procedures at The University of Texas M.D. Anderson Cancer Center, including Houston Area Locations.
- •Able to understand and personally provide informed consent.
- •Willing to allow prospective collection, banking, storage, and research use of biospecimens and associated clinical information as described in the informed consent document.
排除标准
- •Age younger than 18 years.
- •Unable to understand the study information or unable to personally provide informed consent.
- •Declines participation.
- •No known or suspected urothelial carcinoma or other related malignancy of the urinary tract, and no clinical circumstance in which enrollment under this protocol is relevant to the study objectives.
- •Clinical, operational, or safety circumstances that make enrollment or research collection inappropriate or not feasible in the judgment of the treating clinical team or study investigators. Examples may include urgent clinical priorities, insufficient residual specimen after diagnostic needs are met, inability to safely obtain research specimens during a clinically indicated procedure, or inability to complete consent appropriately.
- •Prisoners or other populations requiring additional regulatory protections not specifically approved under this protocol.
结局指标
主要结局
Overall Survival
时间窗: Through study completion; an average of 1 year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
基于 BDA 技术的单基因病 PGT 检测试剂及体系研发ChiCTR2200066794上海市 2022 年度“科技创新行动计划”生物医药科技支撑专项项目
Unknown
不适用
请联系我们上传伦理审批文件。 高通量测序揭示白塞综合征 TCR 组库动态特征的研究白塞综合征ChiCTR2100052641华东医院院级课题100
尚未招募
不适用
Role of Bcl-2 and Ki67 in endometrial lesionsCTRI/2024/02/062918Pragya chitravanshi60
招募中
不适用
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based TherapyOvarian CancerNCT07361471Centre Jean Perrin55
Unknown
不适用
弥漫大 B 细胞淋巴瘤发生发展机制的多组学研究ChiCTR2300075412昆明医科大学第二附属医院